Expanding Mental Healthcare Outreach Will Unlock Future Potential

Key Takeaways

• Strategic provider programs and operational improvements are enhancing patient conversion, driving higher procedure volumes, and improving operating margins.
  
• Expansion into adolescent care and broader market acceptance are creating new revenue streams, supporting sustained multi-year growth and brand differentiation.
  
• Rising costs and reliance on lower-margin, clinic-based revenue stream threaten profitability and future growth, especially amid industry shifts toward digital and more scalable therapeutic solutions.

Catalysts

Engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.

• Adoption of the Provider Connection Program, targeting primary care providers and broadening outreach beyond psychiatrists, is demonstrating a much higher patient conversion rate and has already led to a meaningful increase in referrals. This targeted strategy is expected to drive higher procedure volumes and accelerate revenue growth as awareness and acceptance of treatment expands.
  
• Increasing adolescent patient starts, driven by expanded insurance coverage and new clinical data demonstrating NeuroStar's efficacy and safety in this population, positions Neuronetics to capture previously underserved demand and access a growing and differentiated revenue stream.
  
• Efficiency gains from operational improvements-including self-check-in kiosks, enhanced patient intake processes, and consulting-driven cost structure reviews-are poised to drive operating leverage, lower costs, and improve net margins as patient throughput increases without added headcount.
  
• Expansion of the Better Me Provider (BMP) program is resulting in participating sites treating three times more patients per quarter and responding to patients twice as quickly as non-participants, supporting revenue growth and enhancing brand value through superior care delivery and patient outcomes.
  
• Broader societal acceptance of proactive mental healthcare, growing insurance coverage for new modalities, and ongoing direct-to-consumer and physician education campaigns continue to expand the total addressable market and are anticipated to sustain multi-year topline growth and potential margin expansion as scale is achieved.

Neuronetics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Neuronetics's revenue will grow by 12.6% annually over the next 3 years.
• Analysts are not forecasting that Neuronetics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Neuronetics's profit margin will increase from -26.1% to the average US Medical Equipment industry of 12.8% in 3 years.
• If Neuronetics's profit margin were to converge on the industry average, you could expect earnings to reach $27.3 million (and earnings per share of $0.34) by about May 2029, up from -$39.0 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.9x on those 2029 earnings, up from -3.5x today. This future PE is lower than the current PE for the US Medical Equipment industry at 23.8x.
• Analysts expect the number of shares outstanding to grow by 5.25% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.54%, as per the Simply Wall St company report.

Risks

• Gross margin declined significantly (from 74% to 46.6%) following the Greenbrook acquisition, with Greenbrook's clinic business and SPRAVATO buy-and-bill revenue operating at much lower margins-if this trend persists, it could erode long-term profitability and net earnings.
  
• Operating expenses have increased meaningfully (25% YoY), with full-year guidance revised upward ($100–$105M vs. prior $90–$98M), partly due to the integration of Greenbrook's higher overhead-persistent high opex in excess of revenue growth pressures net margins and undermines the path to consistent profitability.
  
• Revenue growth is becoming more dependent on the lower-margin clinic business and the SPRAVATO buy-and-bill model, which faces challenges around reimbursement variability and profitability-potential payer pushback and reimbursement delays could limit top-line growth and cash collections.
  
• Neuronetics remains heavily reliant on a single core product (NeuroStar TMS), with limited diversification-adverse clinical data, superior competing therapies (e.g., digital therapeutics or new pharmacological treatments), or technological obsolescence could sharply impact long-term revenues.
  
• The industry's growing preference for scalable, cost-effective digital therapeutics and shifting reimbursement models may reduce the addressable market for device-based, in-clinic solutions, threatening Neuronetics' competitive positioning and future topline trajectory.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $4.33 for Neuronetics based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $7.0, and the most bearish reporting a price target of just $3.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $213.2 million, earnings will come to $27.3 million, and it would be trading on a PE ratio of 16.9x, assuming you use a discount rate of 9.5%.
• Given the current share price of $1.94, the analyst price target of $4.33 is 55.2% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.